Streetbeat News

CALC

CalciMedica, Inc.

https://www.calcimedica.com

Industry

Biotechnology

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

Open

3.50

Mkt cap

47M

Volume

113K

High

3.57

P/E Ratio

-20.41

52-wk high

8.38

Low

3.41

Div yield

N/A

52-wk low

2.68

CalciMedica shares rose following the announcement of positive Phase 2B trial results for auxora in treating acute pancreatitis with systemic inflammatory response syndrome.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 2:28 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. Ensysce Biosciences, AtriCure, CalciMedica, Matinas BioPharma, Cue Biopharma, and HOOKIPA Pharma saw notable gains, while Applied DNA Sciences, AnaptysBio, Spero Therapeutics, GlycoMimetics, Tempest Therapeutics, and CVRx experienced declines.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 12:08 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. Ensysce Biosciences, CalciMedica, Matinas BioPharma, AtriCure, Cue Biopharma, and HOOKIPA Pharma saw notable gains, while Applied DNA Sciences, AnaptysBio, Spero Therapeutics, GlycoMimetics, Tempest Therapeutics, and CVRx experienced declines.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 12:08 pm

CalciMedica announced positive results from its Phase 2B Carpo trial of Auxora for treating acute pancreatitis with systemic inflammatory response syndrome. The data was presented at the American College of Gastroenterology 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:22 am

Insider buying activity has been observed in penny stocks such as CalciMedica, Zevia PBC, and Ault Alliance. These transactions may indicate confidence in the companies' prospects. CalciMedica's CEO bought shares following a narrower-than-expected loss, Zevia's director purchased shares despite a wider-than-expected loss, and Ault Alliance's executive chairman acquired shares ahead of a corporate name change.

Portfolio Pulse from Avi Kapoor

August 28, 2024 | 12:58 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on CalciMedica (NASDAQ:CALC) and maintained a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 6:05 pm

CalciMedica (NASDAQ:CALC) reported a Q2 2024 adjusted EPS of $(0.36), beating the analyst consensus estimate of $(0.53) by 32.08%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:14 pm

Merck & Co., Inc. (NYSE:MRK) shares fell 10% after the company reported second-quarter financial results and cut its FY24 adjusted EPS guidance below estimates. Despite beating revenue and EPS estimates, the guidance cut led to a sharp decline. Other stocks such as Imunon, Inc. (NASDAQ:IMNN) and JetBlue Airways Corporation (NASDAQ:JBLU) saw significant gains due to positive news, while QXO, Inc. (NASDAQ:QXO) and VBI Vaccines Inc. (NASDAQ:VBIV) experienced substantial losses.

Portfolio Pulse from Avi Kapoor

July 30, 2024 | 5:53 pm

CalciMedica has been added to the Russell Microcap Index, which could increase its visibility and attract more investors.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 12:11 pm

CalciMedica shares are trading lower after initially gaining on the announcement of topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 4:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.